parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Sun
Heather K
HK
Du
Xiaoli
X
DeRyke
C Andrew
CA
Doern
Gary V
GV
Nicolau
David P
DP
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D027101:DNA Topoisomerase IV / Q000235:genetics*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009154:Mutation; D015242:Ofloxacin / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015242:Ofloxacin; D027101:DNA Topoisomerase IV; D000077266:Moxifloxacin